Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

"Elon Musk is right," the senator tweeted. "The Pentagon, with a budget of $886 billion, just failed its 7th audit in a row.

We recently published a list of 12 Best ADR Stocks To Invest In According to Analysts. In this article, we are going to take ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Macy’s is investigating how hundreds of millions of dollars were hidden by one employee. The retailer delayed its quarterly ...

In fact, Viking just gave investors an update which firms up its status as a very promising company. Here's what it reported, ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from ...